Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORRIF: Rifaximin vs Norfloxacin for SBP Prophylaxis
NCT06199843Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rifaximin in spontaneous bacterial peritonitis (SBP) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Incidence of recurrence of SBP within 6 months. Status: unknown.
02
Drugs
rifaximin
03
Conditions
spontaneous bacterial peritonitis (SBP)
Beyond the preview
Go deeper on NCT06199843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199843.